Log In
BCIQ
Print this Print this
 

rapastinel (GLYX-13) (formerly NT-13)

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionGlycine site functional partial agonist (GFPA) of the NMDA receptor
Molecular Target NMDA receptor
Mechanism of ActionNMDA receptor modulator
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$560.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/31/2015

Undisclosed

$560.0M

Undisclosed

Get a free BioCentury trial today